Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,304 shares of the biopharmaceutical company’s stock after selling 5,623 shares during the period. Teacher Retirement System of Texas’ holdings in Amicus Therapeutics were worth $492,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Peregrine Capital Management LLC lifted its stake in Amicus Therapeutics by 3.4% in the 1st quarter. Peregrine Capital Management LLC now owns 910,508 shares of the biopharmaceutical company’s stock valued at $7,430,000 after buying an additional 29,991 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Amicus Therapeutics by 53.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 8,567 shares during the last quarter. Diversified Trust Co lifted its position in Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 1,784 shares during the period. SG Americas Securities LLC boosted its position in shares of Amicus Therapeutics by 137.6% in the first quarter. SG Americas Securities LLC now owns 100,993 shares of the biopharmaceutical company’s stock worth $824,000 after acquiring an additional 58,496 shares during the last quarter. Finally, Procyon Advisors LLC grew its stake in shares of Amicus Therapeutics by 74.5% during the 1st quarter. Procyon Advisors LLC now owns 42,576 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 18,184 shares during the period.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $6.07 on Thursday. The company has a 50-day moving average price of $6.06 and a two-hundred day moving average price of $7.71. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -67.44 and a beta of 0.51. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

Analyst Ratings Changes

Several research analysts recently commented on FOLD shares. The Goldman Sachs Group cut their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.